Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[THE INVESTOR] ST Pharm announced on Sept. 19 that it has signed a 152 billion won (US$135.50 million) contract with Gilead Sciences Ireland to supply anti-viral active pharmaceutical ingredient for hepatitis C treatment.
ST Pharm has been providing the ingredient to Gilead Sciences -- a US-based pharmaceutical company -- that manufactures Sovaldi and Harvoni, treatments for hepatitis C.
The contract amounts to 110 percent of the South Korean company’s revenue last year and the contract lasts from Jan. 1 to Nov. 30, 2017.
ST Pharm is a contract manufacturing organization unit of pharmaceutical heavyweight Dong-A Socio Group, and its revenue from exporting active ingredients for Gilead’s hepatitis C drugs accounted for about 60 percent of its total revenue of 138 billion won in 2015. It went public in June.
By Hwang You-mee (glamazon@heraldcorp.com)
ST Pharm has been providing the ingredient to Gilead Sciences -- a US-based pharmaceutical company -- that manufactures Sovaldi and Harvoni, treatments for hepatitis C.
The contract amounts to 110 percent of the South Korean company’s revenue last year and the contract lasts from Jan. 1 to Nov. 30, 2017.
ST Pharm is a contract manufacturing organization unit of pharmaceutical heavyweight Dong-A Socio Group, and its revenue from exporting active ingredients for Gilead’s hepatitis C drugs accounted for about 60 percent of its total revenue of 138 billion won in 2015. It went public in June.
By Hwang You-mee (glamazon@heraldcorp.com)
